Mathivanan Sakthikumar, Devesa Isabel, Changeux Jean-Pierre, Ferrer-Montiel Antonio
Instituto de Biología Molecular y Celular, Universitas Miguel Hernández Elche, Spain.
College de FranceParis, France; Centre Nationale de la Recherche Scientifique, Institute Pasteur, Unité de Recherche AssociéeParis, France.
Front Pharmacol. 2016 Jun 23;7:178. doi: 10.3389/fphar.2016.00178. eCollection 2016.
Transient receptor potential vanilloid I (TRPV1) sensitization in peripheral nociceptors is a prominent phenomenon that occurs in inflammatory pain conditions. Pro-algesic agents can potentiate TRPV1 activity in nociceptors through both stimulation of its channel gating and mobilization of channels to the neuronal surface in a context dependent manner. A recent study reported that ATP-induced TRPV1 sensitization in peptidergic nociceptors involves the exocytotic release of channels trafficked by large dense core vesicles (LDCVs) that cargo alpha-calcitonin gene related peptide alpha (αCGRP). We hypothesized that, similar to ATP, bradykinin may also use different mechanisms to sensitize TRPV1 channels in peptidergic and non-peptidergic nociceptors. We found that bradykinin notably enhances the excitability of peptidergic nociceptors, and sensitizes TRPV1, primarily through the bradykinin receptor 2 pathway. Notably, bradykinin sensitization of TRPV1 in peptidergic nociceptors was significantly blocked by inhibiting Ca(2+)-dependent neuronal exocytosis. In addition, silencing αCGRP gene expression, but not substance P, drastically reduced bradykinin-induced TRPV1 sensitization in peptidergic nociceptors. Taken together, these findings indicate that bradykinin-induced sensitization of TRPV1 in peptidergic nociceptors is partially mediated by the exocytotic mobilization of new channels trafficked by αCGRP-loaded LDCVs to the neuronal membrane. Our findings further imply a central role of αCGRP peptidergic nociceptors in peripheral algesic sensitization, and substantiate that inhibition of LDCVs exocytosis is a valuable therapeutic strategy to treat pain, as it concurrently reduces the release of pro-inflammatory peptides and the membrane recruitment of thermoTRP channels.
外周伤害感受器中的瞬时受体电位香草酸亚型1(TRPV1)敏化是炎症性疼痛状态下出现的一个突出现象。促痛剂可通过刺激其通道门控以及以依赖于环境的方式将通道转运至神经元表面,增强伤害感受器中TRPV1的活性。最近一项研究报道,三磷酸腺苷(ATP)诱导的肽能伤害感受器中TRPV1敏化涉及由装载α-降钙素基因相关肽α(αCGRP)的大致密核心囊泡(LDCV)转运的通道的胞吐释放。我们推测,与ATP类似,缓激肽也可能利用不同机制使肽能和非肽能伤害感受器中的TRPV1通道敏化。我们发现,缓激肽显著增强肽能伤害感受器的兴奋性,并使TRPV1敏化,主要通过缓激肽受体2途径。值得注意的是,抑制钙依赖性神经元胞吐作用可显著阻断缓激肽对肽能伤害感受器中TRPV1的敏化作用。此外,沉默αCGRP基因表达而非P物质,可大幅降低缓激肽诱导的肽能伤害感受器中TRPV1的敏化作用。综上所述,这些发现表明,缓激肽诱导的肽能伤害感受器中TRPV1敏化部分是由装载αCGRP的LDCV转运的新通道向神经元膜的胞吐转运介导的。我们的发现进一步暗示αCGRP肽能伤害感受器在周围性痛觉敏化中起核心作用,并证实抑制LDCV胞吐作用是一种有价值的疼痛治疗策略,因为它同时减少促炎肽的释放和热TRP通道的膜募集。